Acquired Hemophilia Treatment & Management
- Author: Sara J Grethlein, MD; Chief Editor: Srikanth Nagalla, MBBS, MS, FACP more...
Treatment strategies for acquired hemophilia have two major objectives. During acute bleeding episodes, effective control of bleeding manifestations is the primary objective. However, the ultimate therapeutic goal is to eliminate the inhibitor and cure the disease.
The treatments used to accomplish these objectives usually depend on the natural history of acquired hemophilia, the clinical presentation of the coagulopathy, and the titer of the inhibitor (expressed in Bethesda units [BU]). Most patients with acquired hemophilia are older and may have many concomitant diseases, and, thus, may require an individualized therapeutic approach. Frequently, treatment of the underlying disorder or the discontinuation of an offending drug may eliminate or assist in the eradication of the inhibitor.
Patients with acquired hemophilia A can bleed after negligible or minor trauma, and may even bleed spontaneously. Any physical activity may trigger bleeding in soft tissues. Until inhibitors are eradicated, patients with acquired hemophilia should avoid activities with a significant risk of trauma.
Patients who have mild bleeding episodes may not require hemostatic therapy (see the image below). In these patients, immunosuppressive therapy should be initiated as soon as the diagnosis of acquired hemophilia is established, when indicated.
A study of practically all patients who presented with acquired hemophilia A in the United Kingdom over a 2-year period reported that the severity of bleeding did not correlate with FVIII level or inhibitor titer and was not useful in predicting those patients who would have fatal bleeding or those who may not require hemostatic treatment.
Consequently, whether patients should receive hemostatic therapy should depend on their bleeding symptoms and not on their FVIII activity or inhibitor levels. However, considering inhibitor levels may be useful in selecting hemostatic therapy in patients who require it.
Common treatments used in the management of patients with inhibitors to clotting factors other than factor VIII (FVIII) are listed elsewhere (see Etiology).
Please see the following for more information:
Hemostatic Therapy for Moderate or Severe Bleeding, FVIII < 5 BU
In patients with acquired hemophilia and low levels of inhibitors (<5 BU), increasing plasma FVIII levels to 30-50% by using agents that increase FVIII concentrations may achieve hemostasis, but this is not predictable a priori, and experience with the patient’s pattern of bleeding and response to therapies is necessary.
Administering infusions of FVIII to patients with low-titer inhibitors may facilitate hemostasis. The dosing requirements for FVIII concentrate are considerably higher in these patients than in patients with congenital hemophilia; occasionally, massive doses are required, and even these massive doses are not always effective.[8, 11] Ultimately, using FVIII concentrates may only delay the need for more effective therapies.
Because of the variable kinetics of acquired antibodies, the required dose of FVIII concentrate can be only roughly predicted from the inhibitor titer. Some clinicians double or triple the dose of FVIII that should be given to a congenital hemophilia patient of the same weight.[19, 31] A dose of FVIII 200 IU/kg IV bolus every 8-12 hours has been recommended. There are no published studies guide the dosing of human FVIII in acquired hemophilia.
Historically, porcine factor VIII has provided a good effect. A porcine sequence recombinant FVIII (Obizur) was approved by the U.S. Food and Drug Administration in October 2014 for treatment of bleeding episodes in adults with acquired hemophilia.
Patients with very low inhibitor titers (<3 BU) and residual FVIII activity may also benefit from treatment with desmopressin (1-deamino-8-D-arginine vasopressin). In healthy individuals, intravenous (IV) infusion of desmopressin (0.3 µg/kg) may result in a two- to three-fold temporary increase in FVIII and von Willebrand factor (vWF) plasma levels. However, in most patients with acquired FVIII inhibitors, desmopressin treatment alone will not provide hemostasis.
Hemostatic Therapy for Moderate to Severe Bleeding, FVIII ≥5 BU
When the inhibitor titer is high (≥5 BU), FVIII concentrates and desmopressin cannot overcome the FVIII-inhibiting capacity by increasing FVIII activity and are ineffective.[9, 30] Consequently, patients with severe bleeding and inhibitor titers of 5 BU or higher should receive therapy with an agent that bypasses FVIII—namely, either with recombinant factor VIIa (rFVIIa) or an activated prothrombin complex concentrate (APCC).
Considerations such as the location of bleeding, the severity of bleeding, comorbidities, treatment availability, and treatment cost may help clinicians select a hemostatic therapy. Monitoring the efficacy of these agents by means of standard measures of coagulation, such as prothrombin time (PT) or activated partial thromboplastin time (aPTT), is not useful.
Recombinant antihemophilic factor, porcine sequence
Porcine sequence recombinant FVIII (Obizur) was approved by the U.S. Food and Drug Administration in October 2014 for treatment of bleeding episodes in adults with acquired hemophilia. Approval was based on a phase II/III global, prospective, controlled, multicenter, open-label trial that studied efficacy in the treatment of serious bleeding episodes in adults with hemophilia A (n=28). All patients treated with porcine sequence recombinant FVIII demonstrated a positive response, defined as an effective or partially effective response with bleeding stopped or reduced and clinical improvement at 24 hours after the initial infusion. A total of 86% had successful treatment of the initial bleeding episode.
Recombinant factor VII
Initially developed for use in patients with congenital hemophilia with alloantibody inhibitors, rVIIa has been successfully used in patients with acquired hemophilia. It binds to the surface of activated platelets, where it supports thrombin generation and bypasses the need for FVIII.[34, 8]
Recommended dosing is 90-120 mg/kg IV bolus every 2-3 hours until bleeding is stopped. If no response is seen after 2 doses, 120-270 mg/kg IV bolus every 2.5-3 hours should be administered. Minor bleeding episodes are usually treated with 2 or 3 doses, but several days of treatment may be required for major bleeding episodes. Patients who do not respond within 24 hours are unlikely to respond if rFVIIa treatment is continued.
Early studies of rFVIIa as a second-line agent for the treatment of acquired hemophilia showed a complete response rate in 75% of bleeding episodes. A more recent analysis from an Italian registry of acquired hemophilia has demonstrated that rFVIIa controlled bleeding in 90% of the 20 cases in which it was used (in 19 cases as first-line therapy and in 1 case as salvage treatment).
In a United States study from the Hemostasis & Thrombosis Research Society (HTRS) Registry, rFVIIa was used as first-line treatment in 127 bleeding episodes and as second-line in 12. Physician-rated efficacy of rFVIIa was reported as 'bleeding stopped' in 85% of episodes, 'bleeding slowed' in 11%, and 'no improvement' in 4%. Another HTRS study, in patients with acquired hemophilia who underwent surgical or invasive procedures, reported that rFVIIa provided adequate hemostasis for 91% of procedures (20 of 22), with no thromboembolic events reported.
rFVIIa is well tolerated and has few adverse effects. One advantage of rVIIa is that it does not have the potential to transmit human pathogens, because it is made from cultured mammalian cells and is free from human pathogens. No anamnestic risk in inhibitors with the use of rFVIIa has been described.
Arterial and venous thrombosis have been reported with the use of rVIIa.[8, 39] Treatment with rFVIIa concentrate was associated with venous thromboembolism in a review of data from the Adverse Event Reporting System (AERS) of the US Food and Drug Administration (FDA). However, most reported thromboembolic events followed the use of rFVIIa for off-label indications, not its use for people with hemophilia with inhibitors. The thrombogenicity of any agent used to treat bleeding may be of particular concern in older individuals.
In a comprehensive meta-analysis of 35 randomized clinical trials of rFVIIa use in nonhemophiliacs, those who were treated with high doses of rFVIIa on an off-label basis experienced a substantially higher risk of arterial, but not venous, thromboembolic events. Elderly individuals were particularly susceptible to this adverse event. Neither arterial nor venous hypercoagulability has been noted in individuals who received rFVIIa to prevent or treat bleeding complications associated with their acquired hemophilia.
Activated prothrombin complex concentrate
APCCs are other FVIII-bypassing agents used to manage bleeding episodes in acquired hemophilia. Currently, the only APCC available in the United States is FEIBA (Baxter-Immuno). FEIBA, an anti-inhibitor coagulant complex, is a plasma-derived concentrate containing activated clotting factors that has undergone viral inactivation with dry heat vapor treatment.[8, 35]
The recommended dosage for anti-inhibitor coagulant complex is 50-100 IU/kg IV bolus every 8-12 hours. The total dose should not exceed 200 U/Kg within a 24-hour period. Because no assay is available to monitor response to anti-inhibitor coagulant complex, clinicians should use their judgment to determine duration of treatment.
A retrospective study of APCC use as first-line therapy in patients with acquired hemophilia has shown an overall complete response rate of 86% with a dosing regimen of 75 U/kg every 8-12 hours (median dose number, 10).
Concerns regarding the risk of thrombotic adverse effects (including myocardial infarction) with APCC treatment have been raised, particularly among patients with acquired hemophilia, many of whom are elderly, have a malignancy, or are postpartum. However, if doses of APCC do not exceed the manufacturers’ recommendations, thrombotic adverse effects are infrequent.
It should be noted that large doses of APCCs may trigger an anamnestic rise in inhibitor titer because they may contain some FVIII.[11, 42] Being derived from plasma, APCCs do have the potential to transmit infection; however, there has never been a documented case of transmitted bloodborne virus in congenital or acquired hemophilia.
Patients who do not respond to rFVIIa or APCC can either receive a combination of the 2 agents or undergo immunoadsorption/plasmapheresis (see below).
There is emerging evidence that in individuals with alloantibody-related bleeding who do not respond to either APCC or rFVIIa used alone, the combination of APCC with rVIIa may be useful. This combined approach has not been used systematically in acquired inhibitor patients; however, in off-label settings, it has been associated with high morbidity and mortality from thrombogenesis in adults. If combined therapy with APCC or rFVIIa is administered, clinicians should carefully monitor the patient for hypercoagulable complications.
Immunoadsorption or plasmapheresis
Temporary reduction of the inhibitor titer through extracorporeal removal of the autoantibody should be considered in patients with high inhibitor titers and severe hemorrhages and in those who do not respond to rFVIIa or APCC.
Extracorporeal autoantibody removal can be accomplished by using therapeutic plasmapheresis or specific immunoadsorption of immunoglobulins.[1, 43, 44, 45, 46, 47] Unfortunately, no Sepharose columns are currently available in the United States to accomplish this. Immunoadsorption may be particularly useful when a rapid reduction in the inhibitor titer is required. After plasmapheresis or immunoadsorption, FVIII replacement should be initiated to achieve hemostasis.
Eradication of Inhibitor
Guidelines suggest that as soon as the diagnosis of acquired hemophilia is established, elimination of the inhibitor should be attempted by means of immunosuppression (see the image below). Eradicating the inhibitor is important to restore normal hemostasis and minimize the patient’s risk of bleeding. Patients who achieve complete remission (eradication of the inhibitor) have been shown to have a better outcome in terms of overall survival than patients who do not achieve complete remission.
In patients with mild hemorrhagic symptoms and low levels of inhibitors, immunosuppressive therapy may not be required to eliminate the inhibitor. About 25% of patients will achieve spontaneous remission without immunosuppression.
Drug-induced or pregnancy-associated autoantibodies frequently resolve spontaneously, whereas those associated with underlying autoimmune diseases rarely spontaneously resolve. Because patients remain at risk for fatal bleeding until the inhibitor is eradicated, and there are no clinical laboratory features that identify all high-risk patients, all patients should be immunosuppressed as soon as the diagnosis is made.
First-line therapy for eradicating inhibitors usually includes methylprednisolone at a dose of 1 mg/kg/day (or an equivalent dose of prednisone), which results in the abolition of inhibitors in approximately 60-70% of patients.[16, 19] Adding oral cyclophosphamide 50-150 mg/d can increase the response rate to 70-80%.[16, 19] However, the overall survival and disease-free survival are the same for steroids as for steroids plus cytotoxic agents.[16, 19]
Cyclophosphamide has also been administered IV at high intermittent doses. In addition, a nonrandomized study reported no difference between treatment with steroids alone and treatment with steroids plus cytotoxic agents. Other cytotoxic agents that have been used include azathioprine, vincristine, mycophenolate mofetil, and 2-chlorodeoxyadenosine.[8, 14, 49, 50, 51]
Because alkylating agents may cause infertility, alopecia, myelosuppression, and other adverse effects, prednisolone alone or combined with azathioprine may be preferred for patients with acquired hemophilia associated with pregnancy. Response is typically seen in 3-6 weeks, but some patients may not show response for months. Because relapse may occur when immunosuppression is stopped or reduced, premature discontinuance of therapy should be avoided.
Rituximab, an anti-CD20 monoclonal antibody, has shown promising results in eradicating inhibitors in acquired hemophilia.[8, 52, 53, 54, 55] The usual dose is 375 mg/m2 each week for 4 weeks. Most responses are seen within 2 weeks. The current consensus is that rituximab should be considered in patients who are resistant to first-line therapy or who cannot tolerate standard immunosuppressive therapy.
Some authors, however, have proposed that rituximab should be included as first-line therapy in combination with prednisone for patients whose inhibitor titers are higher than 5 but lower than 30 BU and in combination with prednisone and cyclophosphamide for patients whose titers are higher than 30.[54, 8] At present, there are no results from randomized controlled trials to confirm the usefulness of rituximab as a first-line or salvage therapy for acquired hemophilia.
Cyclosporine has been used as salvage therapy alone or with prednisolone, but it is particularly effective in patients with underlying systemic lupus erythematosus. Because of cyclosporine’s toxicities and adverse effects, serum levels should be monitored. Successful treatment with cyclosporine can usually be discontinued after 1 year of therapy.
Intravenous immunoglobulin (IVIG) may be useful as a second-line therapy for patients who do not initially respond to immunosuppression. However, a large retrospective study showed no benefit when high-dose IVIG was added to prednisolone or cytotoxic agents. Another study reported that adding IVIG to immunosuppressive regimens does not affect rates of complete remission and survival. This should be reserved as first-line treatment for those with low antibody titers.
Immune tolerance induction
Immune tolerance induction regimens involving immunosuppression and immunoadsorption (eg, the modified Bonn-Malmö regimen) also have been shown to rapidly eradicate autoantibody inhibitors.[32, 56]
In one study, 35 patients with acquired hemophilia and severe bleeding were treated with a combination of cyclophosphamide, prednisolone, large volume immunoadsorption, IVIG, and FVIII, and treatment appeared to achieve rapid remission in the vast majority of patients. This approach is a potentially useful treatment option for those with severe bleeding.
Surgical Control of Acute Hemorrhage
Surgical management may be required to help some patients with acquired hemophilia survive acute life-threatening bleeding episodes. Techniques that may help stop these hemorrhages are classified as mechanical, thermal, or chemical.
Mechanical procedures that close a bleeding point or prevent blood from entering the area of disruption by ligature placement or selective embolization may be useful.
Heat (eg, electrocautery) can denature protein and result in coagulation of bleeding tissue, while cryotherapy may cause dehydration and denaturation of lipid molecules and facilitate the cessation of bleeding.
Some chemical agents possess hygroscopic properties that increase their bulk and aid in plugging disrupted blood vessels. Certain chemical agents, such as micronized collagen, may also minimize blood loss by serving as hemostatic agents.
Anti-inhibitor coagulant complex (FEIBA) has been demonstrated in small studies to provide adequate hemostasis to permit surgery in patients with acquired inhibitors.
Special Treatment Concerns
The advanced age of patients with acquired hemophilia and the presence of comorbid conditions may preclude the most aggressive treatments and necessitate dose reductions (eg, steroids in diabetes), which may lead to a lower response rate and, thus, a decreased survival rate.
Immunosuppressive agents are associated with multiple adverse effects, particularly in elderly persons, the age group in which acquired hemophilia is most common. Common adverse effects include cytopenia, alopecia, toxic hepatitis, and severe bacterial infections. In a recent analysis of 172 patients with acquired hemophilia, about half of the cohort experienced morbidity unrelated to bleeding (usually due to the adverse effects of immunosuppression). Nonetheless, patients who receive immunotherapy typically do better than patients who do not.
Careful selection and close monitoring of immunosuppressive therapy is critical.
Although cyclophosphamide may enhance inhibitor eradication, it is associated with severe adverse effects, especially in elderly persons. In fact, a substantial proportion of patients die as a result of complications associated with this agent, primarily neutropenia-related infections.[19, 13]
In patients with acquired hemophilia and an underlying malignancy, the primary malignancy should be treated because it is easier to eradicate the antibody when the tumor is controlled.[19, 59] Moreover, the presence of a malignancy is not a contraindication to the use of immunosuppression to eradicate the antibody, even in cases that do not respond to treatment of the tumor. However, the decision to initiate immunosuppressive therapy should take into account other factors (eg, patient age, malignancy type, and bleeding severity).
Severe bleeding can occur from trivial injuries, intramuscular injections, intra-arterial blood sampling, and invasive procedures, all of which should be prevented. To minimize the risk of bleeding in patients with acquired hemophilia, it is important to avoid situations that may place patients at high risk for bleeding, at least until they are in remission.
Consultations and Further Care
Because acquired hemophilia can be difficult to diagnose and causes significant morbidity and mortality, it may be prudent to refer patients in whom acquired hemophilia is suggested to a center that has laboratory and clinical experience in the disorder, as well as the necessary pharmacy and blood bank support.[22, 8]
Hospitalizing patients with internal bleeding or with uncontrollable bleeding is advised. Constant clinical evaluation to ensure adequacy of treatment, pain relief, and other supportive care is necessary. The hematologist must be centrally involved to coordinate care.
Because relapse has been reported in approximately 1 in 5 patients after immunosuppressive therapy is discontinued, long-term follow-up of patients with acquired hemophilia is recommended.
Kessler CM, Knöbl P. Acquired haemophilia: an overview for clinical practice. Eur J Haematol. 2015 Dec. 95 Suppl 81:36-44. [Medline].
Franchini M, Mannucci PM. Acquired haemophilia A: A 2013 update. Thromb Haemost. 2013 Sep 5. 110(20130905):[Medline].
Von Depka M. NovoSeven: mode of action and use in acquired haemophilia. Intensive Care Med. 2002 Oct. 28 Suppl 2:S222-7. [Medline].
Boggio LN, Green D. Acquired hemophilia. Rev Clin Exp Hematol. 2001 Dec. 5(4):389-404; quiz following 431. [Medline].
Cohen AJ, Kessler CM. Acquired inhibitors. Baillieres Clin Haematol. 1996 Jun. 9(2):331-54. [Medline].
Knobe KE, Villoutreix BO, Tengborn LI, Petrini P, Ljung RC. Factor VIII inhibitors in two families with mild haemophilia A: structural analysis of the mutations. Haemostasis. 2000 Sep-Oct. 30(5):268-79. [Medline].
Barrow RT, Healey JF, Jacquemin MG, Saint-Remy JM, Lollar P. Antigenicity of putative phospholipid membrane-binding residues in factor VIII. Blood. 2001 Jan 1. 97(1):169-74. [Medline].
Ma AD, Carrizosa D. Acquired factor VIII inhibitors: pathophysiology and treatment. Hematology Am Soc Hematol Educ Program. 2006. 432-7. [Medline].
Franchini M. Acquired hemophilia A. Hematology. 2006 Apr. 11(2):119-25. [Medline].
Green D, Blanc J, Foiles N. Spontaneous inhibitors of factor VIII: kinetics of inactivation of human and porcine factor VIII. J Lab Clin Med. 1999 Mar. 133(3):260-4. [Medline].
Hay CR. Acquired haemophilia. Baillieres Clin Haematol. 1998 Jun. 11(2):287-303. [Medline].
Shaligram D, Alqassem T, Koby E. Desvenlafaxine as a possible cause of acquired hemophilia. Gen Hosp Psychiatry. 2010 Nov-Dec. 32(6):646.e13-5. [Medline].
Collins PW, Hirsch S, Baglin TP, Dolan G, Hanley J, Makris M, et al. Acquired hemophilia A in the United Kingdom: a 2-year national surveillance study by the United Kingdom Haemophilia Centre Doctors' Organisation. Blood. 2007 Mar 1. 109(5):1870-7. [Medline].
Green D, Lechner K. A survey of 215 non-hemophilic patients with inhibitors to Factor VIII. Thromb Haemost. 1981 Jun 30. 45(3):200-3. [Medline].
Morrison AE, Ludlam CA, Kessler C. Use of porcine factor VIII in the treatment of patients with acquired hemophilia. Blood. 1993 Mar 15. 81(6):1513-20. [Medline].
Hay CR, Brown S, Collins PW, Keeling DM, Liesner R. The diagnosis and management of factor VIII and IX inhibitors: a guideline from the United Kingdom Haemophilia Centre Doctors Organisation. Br J Haematol. 2006 Jun. 133(6):591-605. [Medline].
Bolton-Maggs PH, Perry DJ, Chalmers EA, Parapia LA, Wilde JT, Williams MD, et al. The rare coagulation disorders--review with guidelines for management from the United Kingdom Haemophilia Centre Doctors' Organisation. Haemophilia. 2004 Sep. 10(5):593-628. [Medline].
Bouvry P, Recloux P. Acquired hemophilia. Haematologica. 1994 Nov-Dec. 79(6):550-6. [Medline].
Delgado J, Jimenez-Yuste V, Hernandez-Navarro F, Villar A. Acquired haemophilia: review and meta-analysis focused on therapy and prognostic factors. Br J Haematol. 2003 Apr. 121(1):21-35. [Medline].
Tiede A, Hofbauer CJ, Werwitzke S, Knöbl PN, Gottstein S, Scharf RE, et al. Anti-factor VIII IgA as a potential marker of poor prognosis in acquired hemophilia A: results from the GTH-AH 01/2010 Study. Blood. 2016 Feb 24. [Medline].
Seethala S, Collins NP Jr, Comerci G Jr. An Unusual Etiology for Elevation of Activated Partial Thromboplastin Time (aPTT) in SLE: Acquired Hemophilia and Lupus Anticoagulant. Case Rep Hematol. 2013. 2013:521785. [Medline].
Collins PW. Management of acquired haemophilia A--more questions than answers. Blood Coagul Fibrinolysis. 2003 Jun. 14 Suppl 1:S23-7. [Medline].
Chng WJ, Sum C, Kuperan P. Causes of isolated prolonged activated partial thromboplastin time in an acute care general hospital. Singapore Med J. 2005 Sep. 46(9):450-6. [Medline].
Kazmi MA, Pickering W, Smith MP, Holland LJ, Savidge GF. Acquired haemophilia A: errors in the diagnosis. Blood Coagul Fibrinolysis. 1998 Oct. 9(7):623-8. [Medline].
Taher A, Abiad R, Uthman I. Coexistence of lupus anticoagulant and acquired haemophilia in a patient with monoclonal gammopathy of unknown significance. Lupus. 2003. 12(11):854-6. [Medline].
Algiman M, Dietrich G, Nydegger UE, Boieldieu D, Sultan Y, Kazatchkine MD. Natural antibodies to factor VIII (anti-hemophilic factor) in healthy individuals. Proc Natl Acad Sci U S A. 1992 May 1. 89(9):3795-9. [Medline].
Verbruggen B, Novakova I, Wessels H, Boezeman J, van den Berg M, Mauser-Bunschoten E. The Nijmegen modification of the Bethesda assay for factor VIII:C inhibitors: improved specificity and reliability. Thromb Haemost. 1995 Feb. 73(2):247-51. [Medline].
Mahlangu J, Andreeva TA, Macfarlane D, Reding MT, Walsh C, Ritchie B, et al. A phase II open-label study evaluating hemostatic activity, pharmacokinetics and safety of recombinant porcine Factor VIII (OBI-1) in hemophilia A patients with alloantibody inhibitors directed against human FVIII. Blood. (ASH Annual Meeting Abstracts). 2007. 110(11):abstract 783.
Drobiecki A, Pasiarski M, Hus I, Sokolowska B, Watek M. Acquired hemophilia in the patient suffering from rheumatoid arthritis: case report. Blood Coagul Fibrinolysis. 2013 Dec. 24(8):874-80. [Medline].
Grunewald M, Beneke H, Güthner C, Germowitz A, Brommer A, Griesshammer M. Acquired haemophilia: experiences with a standardized approach. Haemophilia. 2001 Mar. 7(2):164-9. [Medline].
Rizza CR, Matthews JM. Effect of frequent factor VIII replacement on the level of factor VIII antibodies in haemophiliacs. Br J Haematol. 1982 Sep. 52(1):13-24. [Medline].
Kessler CM. New perspectives in hemophilia treatment. Hematology Am Soc Hematol Educ Program. 2005. 429-35. [Medline].
Obizur (antihemophilic factor [recombinant], porcine sequence) [package insert]. Westlake Village, CA, USA: Baxter Healthcare Corp. October 2014. Available at [Full Text].
Hoffman M, Monroe DM, Roberts HR. Platelet-dependent action of high-dose factor VIIa. Blood. 2002 Jul 1. 100(1):364-5; author reply 365. [Medline].
Hay CR, Negrier C, Ludlam CA. The treatment of bleeding in acquired haemophilia with recombinant factor VIIa: a multicentre study. Thromb Haemost. 1997 Dec. 78(6):1463-7. [Medline].
Baudo F, de Cataldo F, Gaidano G,. Treatment of acquired factor VIII inhibitor with recombinant activated factor VIIa: data from the Italian registry of acquired hemophilia. Haematologica. 2004 Jun. 89(6):759-61. [Medline].
Ma AD, Kessler CM, Al-Mondhiry HA, Gut RZ, Cooper DL. Use of recombinant activated factor VII for acute bleeding episodes in acquired hemophilia: final analysis from the Hemostasis and Thrombosis Research Society Registry acquired hemophilia study. Blood Coagul Fibrinolysis. 2016 Jan 12. [Medline].
Ma AD, Kessler CM, Al-Mondhiry HA, Gut RZ, Cooper DL. US experience with recombinant factor VIIa for surgery and other invasive procedures in acquired haemophilia: analysis from the Hemostasis and Thrombosis Research Society Registry. Haemophilia. 2016 Jan. 22 (1):e18-24. [Medline].
Guillet B, Pinganaud C, Proulle V, Dreyfus M, Lambert T. Myocardial infarction occurring in a case of acquired haemophilia during the treatment course with recombinant activated factor VII. Thromb Haemost. 2002 Oct. 88(4):698-9. [Medline].
O'Connell KA, Wood JJ, Wise RP, Lozier JN, Braun MM. Thromboembolic adverse events after use of recombinant human coagulation factor VIIa. JAMA. 2006 Jan 18. 295(3):293-8. [Medline].
Levi M, Levy JH, Andersen HF, Truloff D. Safety of recombinant activated factor VII in randomized clinical trials. N Engl J Med. 2010 Nov 4. 363(19):1791-800. [Medline].
Sallah S. Treatment of acquired haemophilia with factor eight inhibitor bypassing activity. Haemophilia. 2004 Mar. 10(2):169-73. [Medline].
Francesconi M, Korninger C, Thaler E, Niessner H, Höcker P, Lechner K. Plasmapheresis: its value in the management of patients with antibodies to factor VIII. Haemostasis. 1982. 11(2):79-86. [Medline].
Sunagawa T, Uezu Y, Kadena K, Tokuyama K, Kinjo F, Saito A. Successful treatment of a non-haemophilic patient with inhibitor to factor VIII by double-filtration plasmapheresis. Br J Haematol. 1999 Mar. 104(3):465-7. [Medline].
Jansen M, Schmaldienst S, Banyai S, Quehenberger P, Pabinger I, Derfler K, et al. Treatment of coagulation inhibitors with extracorporeal immunoadsorption (Ig-Therasorb). Br J Haematol. 2001 Jan. 112(1):91-7. [Medline].
Guillet B, Kriaa F, Huysse MG, Proulle V, George C, Tchernia G, et al. Protein A sepharose immunoadsorption: immunological and haemostatic effects in two cases of acquired haemophilia. Br J Haematol. 2001 Sep. 114(4):837-44. [Medline].
Ogata H, Sakai S, Koiwa F, Tayama H, Kinugasa E, Ideura T, et al. Plasma exchange for acquired hemophilia: a case report. Ther Apher. 1999 Nov. 3(4):320-2. [Medline].
Lottenberg R, Kentro TB, Kitchens CS. Acquired hemophilia. A natural history study of 16 patients with factor VIII inhibitors receiving little or no therapy. Arch Intern Med. 1987 Jun. 147(6):1077-81. [Medline].
Lian EC, Larcada AF, Chiu AY. Combination immunosuppressive therapy after factor VIII infusion for acquired factor VIII inhibitor. Ann Intern Med. 1989 May 15. 110(10):774-8. [Medline].
Eisert S, Mosler K, Laws HJ, Göbel U. Successful use of mycophenolate mofetil and prednisone in a 14-year-old girl with acquired hemophilia A. Thromb Haemost. 2005 Apr. 93(4):792-3. [Medline].
Sallah S, Wan JY. Efficacy of 2-chlorodeoxyadenosine in refractory factor VIII inhibitors in persons without hemophilia. Blood. 2003 Feb 1. 101(3):943-5. [Medline].
Kain S, Copeland TS, Leahy MF. Treatment of refractory autoimmune (acquired) haemophilia with anti-CD20 (rituximab). Br J Haematol. 2002 Nov. 119(2):578. [Medline].
Wiestner A, Cho HJ, Asch AS, Michelis MA, Zeller JA, Peerschke EI, et al. Rituximab in the treatment of acquired factor VIII inhibitors. Blood. 2002 Nov 1. 100(9):3426-8. [Medline].
Aggarwal A, Grewal R, Green RJ, Boggio L, Green D, Weksler BB, et al. Rituximab for autoimmune haemophilia: a proposed treatment algorithm. Haemophilia. 2005 Jan. 11(1):13-9. [Medline].
Maillard H, Launay D, Hachulla E, Goudemand J, Lambert M, Morell-Dubois S, et al. Rituximab in postpartum-related acquired hemophilia. Am J Med. 2006 Jan. 119(1):86-8. [Medline].
Zeitler H, Ulrich-Merzenich G, Hess L, Konsek E, Unkrig C, Walger P, et al. Treatment of acquired hemophilia by the Bonn-Malmo Protocol: documentation of an in vivo immunomodulating concept. Blood. 2005 Mar 15. 105(6):2287-93. [Medline].
Shobeiri SA, West EC, Kahn MJ, Nolan TE. Postpartum acquired hemophilia (factor VIII inhibitors): a case report and review of the literature. Obstet Gynecol Surv. 2000 Dec. 55(12):729-37. [Medline].
Rangarajan S, Yee TT, Wilde J. Experience of four UK comprehensive care centres using FEIBA® for surgeries in patients with inhibitors. Haemophilia. 2011 Jan. 17(1):28-34. [Medline].
Sallah S, Singh P, Hanrahan LR. Antibodies against factor VIII in patients with solid tumors: successful treatment of cancer may suppress inhibitor formation. Haemostasis. 1998 Sep-Oct. 28(5):244-9. [Medline].
Tiede A, Hofbauer CJ, Werwitzke S, Knöbl PN, Gottstein S, Scharf RE, et al. Anti-factor VIII IgA as a potential marker of poor prognosis in acquired hemophilia A: results from the GTH-AH 01/2010 Study. Blood. 2016 Feb 24. [Medline].
|Disease Association||Green 1981 (N = 215), %||Morrison 1993 (N = 65), %||Collins 2007 (N = 172), %|
|Collagen, vascular, and other autoimmune diseases||18.0||17.0||16.7|
|Possible drug reaction||5.6||3.0||NR|
|*In this trial, idiopathic and other were combined.
|Coagulation Factor Inhibited||Most Commonly Associated Disorders||Treatment|
|V||Lymphoproliferative disorders, adenocarcinoma, tuberculosis, aminoglycosides, topical thrombin||FFP, rFVIIa|
|IX||Systemic lupus erythematosus, acute rheumatic fever, hepatitis, collagen vascular diseases, multiple sclerosis, postprostatectomy, and postpartum||FIX concentrates, APCCs, rFVIIa, corticosteroids|
|XI||Autoimmune diseases, prostate carcinoma, chronic lymphocytic leukemia, chlorpromazine||FFP, FXI concentrates, rFVIIa, tranexamic acid, fibrin glue|
|XIII||Idiopathic, isoniazid, penicillin||FXIII concentrate, FFP, stored plasma, cryoprecipitate|
|VWF‡||Autoimmune disorders, monoclonal gammopathies, lymphoproliferative diseases, epidermoid malignancies, hypothyroidism, myeloproliferative disorders, and certain medications||Desmopressin, infusion of FVIII that contains vWF, IVIG, plasma exchange|
|II||Topical thrombin, idiopathic, autoimmune diseases, procainamide||APCC, FFP|
|VII||Bronchogenic carcinoma, idiopathic||FIX concentrates, APCC, FVIII concentrates, rFVIIa, fibrin glue, tranexamic acid|
|X||Amyloidosis, carcinoma, acute nonlymphocytic leukemia, acute respiratory infections, fungicide exposure, idiopathic||APCC, tranexamic acid, fibrin glue, FFP|
|APCC—activated prothrombin complex concentrate; FFP—fresh frozen plasma; IVIG—intravenous immunoglobulin; vWF—von Willebrand factor.|